why choose us

First received: October 05, 2022

Clinical Trial: Cannabidiol as a Treatment for Social Anxiety Disorder (R61)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Social Anxiety Disorder

Study Type: INTERVENTIONAL


Official Title: Randomized Placebo-controlled Trial to Determine the Biological Signature of Cannabidiol as a Treatment for Social Anxiety Disorder (R61)

Brief Summary: The R61 will include two CBD dose levels vs placebo (PBO) and examine potential engagement with two primary targets in a 3-week randomized controlled trial design.Willing and eligible subjects will be randomized to one of three randomized double-blind treatments (n = 20 each group): 1) CBD 800 mg (400 mg twice daily), 2) CBD 400 mg (200 mg twice daily), or 3) PBO twice daily for three weeks.Participation is estimated at approximately 1 month from end of screening to endpoint for the primary R61 study period.This…

Read more